Becker's Clinical Quality & Infection Control

September/October 2021 IC_CQ

Issue link: https://beckershealthcare.uberflip.com/i/1414493

Contents of this Issue

Navigation

Page 47 of 47

#1 Brand in Daily Nasal Decolonization 1. Arden S. Does Universal Nasal Decolonization with an Alcohol-Based Nasal Antiseptic Reduce Infection Risk and Cost? Open Forum Infect Dis 2019 Oct; 6(Suppl 2): S26. 2. References list: nozin.com/clinical-outcomes. Outcomes reported by actual users. Your results may vary. Nozin® Nasal Sanitizer® antiseptic is for nasal decolonization. ©2021 Global Life Technologies Corp. All rights reserved. Made in USA. Nozin®, Nasal Sanitizer®, Popswab® and NOVA SM are trademarks of Global Life Technologies Corp. Nozin® Nasal Sanitizer® antiseptic is an OTC topical drug. No claim is made that it has an effect on any specific disease. Patent nos.: nozin.com/patents. REDUCING MRSA INFECTION RATES BY 96% 1 IS NOT EASY. WE CAN HELP GET YOU THERE. Nozin introduces NOVA SM programs. Nozin, leader in developing and implementing MRSA / MSSA risk mitigation programs, presents NOVA SM . A proprietary suite of tools and services, Nozin NOVA SM programs are guided by experienced consultants and help reduce infection risks, improve care and lower costs in hospitals. NOVA SM programs are working nationwide. The Nozin NOVA SM approach is clinically proven to help reduce MRSA infection risks up to 96%, decrease contact precautions 40%, increase patient as well as staff satisfaction and save up to $1.4 million in a year. 2 NOVA SM is powered by Contact Nozin to learn more about NOVA SM . Visit: nozin.com/nova Call: 877-669-4648 Presents

Articles in this issue

Links on this page

view archives of Becker's Clinical Quality & Infection Control - September/October 2021 IC_CQ